SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst discussions around its association with political figures and recent news, including labor reports and tariff implications. Community talking points involve debates over economic policies, the Epstein files, and the company's valuation. The stock's performance is generating strong opinions and speculative commentary.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as the community rallies around its strong performance within the Injective ecosystem and its potential for high gains. Bullish sentiment is fueled by the anticipation of a staked $INJ ETF, which some believe could drive further momentum for this memecoin. Community members are actively discussing its unique features, such as the burned liquidity pool, and its potential to outperform other meme coins.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming staking updates and airdrop details, creating excitement. The community buzzes about token burns, achieving new milestones, and the potential for future utilities. Brokecoin continues to gain traction within the Solana meme coin ecosystem, fueled by a dedicated community and ongoing development efforts.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

The crypto 4CHAN.X is gaining traction as community members rally around its potential, emphasizing its roots in internet culture and the long-term vision. Some investors are highlighting the coin's scarcity and encouraging others to accumulate, while dismissing negative sentiment. The community also seems to be responding to recent price volatility, reaffirming a commitment to holding.

Cardano is a proof-of-stake blockchain platform designed to support decentralized applications (dApps), featuring a multi-asset ledger and smart contract functionality. Unlike many other blockchains, Cardano is built from the ground up based on original academic research, with proposed solutions undergoing peer review and presentation at international conferences before development. The platform emphasizes a research-driven and formal methods approach to design and implementation.

Cardano

Cardano is trending as the community discusses the launch of Cocky Wings, a food business and memecoin on the Cardano blockchain, generating excitement around real-world asset integration. Discussions also involve potential rate cuts and their impact on crypto markets, with some anticipating a liquidity boost for risk-on assets like Cardano. Additionally, updates on Keeta Anchors and their potential to enhance Cardano's capabilities are circulating.

Krypto Cock is a meme-powered crypto project with real onchain utility. Born from the lessons of past market cycles, $COCK blends humor, culture, and technology to create a unique community-driven ecosystem.  The project is focused on: • Building lightweight mini-apps for Farcaster and other onchain platforms • Developing an engaged, growing community • Delivering consistent, high-quality content • Offering practical onchain tools and experiences • Led by a team with years of crypto and product experience  $COCK aims to make the crypto experience more fun, accessible, and connected, without sacrificing purpose or quality.

CockCardano

$COCK.X is trending as the community rallies around the launch of CockyWings LLC, a real-world food business, generating excitement for its potential revenue streams. The community emphasizes the project's focus on combining a meme-driven approach with tangible utility on the Cardano network. Many are anticipating the potential for long-term growth and real-world adoption.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending amid community debate over its valuation and future catalysts, particularly following recent earnings and raised guidance. Discussions revolve around technical analysis versus fundamental strength, with some highlighting potential for a market correction. Community members are closely watching for news of contract wins or a possible acquisition.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amid speculation surrounding potential inclusion in the S&P 500, with the official announcement expected soon. The community is actively discussing potential price movements based on the outcome, with some bracing for volatility regardless of the decision. Broader market sentiment and the upcoming Robinhood summit are also contributing to the heightened interest in the stock.

WorldFinancial

World Liberty Financial (WLFI.X) is trending as the community discusses its potential role in revolutionizing finance, particularly through its USD1 stablecoin and tokenized real estate initiatives, with some highlighting potential conflicts involving Justin Sun. Community members are debating the token's long-term prospects, its ties to the Trump family, and its relationship with ALTS.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

TransCode Therapeutics ($RNAZ) is trending due to promising Phase 1a trial results for its metastatic cancer drug, TTX-MC138, showing stable disease in some patients and no dose-limiting toxicities, sparking significant community interest. Discussions revolve around the potential for a short squeeze, warrant triggers, and speculation on whether the company will cancel its planned reverse stock split given the recent positive momentum. Investors are closely watching for further news and catalysts, hopeful for continued positive data that could drive the stock higher.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of ZyVersa Therapeutics surged Wednesday, drawing heavy attention from retail investors after the company unveiled new plans to position its inflammasome ASC inhibitor, IC 100, as an adjunct to GLP-1 receptor agonists in addressing obesity-related cardiometabolic complications.The stock closed up&nbsp;over 24% at $0.68 on Wednesday before paring gains in after-hours trading, falling 12.38% to $0.60.In a shareholder letter, CEO Stephen C. Glover outlined a strategy to target inflammation-driven pathways that remain unaddressed by GLP-1 agonists such as semaglutide.&nbsp;While these drugs have transformed obesity treatment by inducing significant weight loss, Glover pointed to high discontinuation rates — up to 85% within two years among non-diabetic patients—and side effects including muscle loss and gastrointestinal issues as key limitations.“While GLP-1 agonists have revolutionized obesity treatment, significant unmet medical needs remain,” Glover wrote.ZyVersa’s IC 100 targets ASC and ASC specks, which play a central role in initiating and perpetuating inflammasome activation.&nbsp;Unlike most inflammasome inhibitors in development that target NLRP3, IC 100 is designed to broadly inhibit several inflammasomes implicated in obesity, insulin resistance, and diabetic nephropathy, including AIM2, NLRP1, NLRC4, and others.Preclinical studies cited by the company demonstrated that IC 100 reduced inflammation and plaque formation in an ApoE knockout model of atherosclerosis, lowered fasting blood glucose in diabetic kidney disease models, and suppressed key proinflammatory cytokines such as IL-1β, IL-18, and IL-6.ZyVersa said it will initiate a preclinical study combining IC 100 with semaglutide in H1 2025, file an Investigational New Drug (IND) application in H2 2025, and begin Phase 1 clinical trials in H1 2026 focusing on overweight individuals with cardiometabolic risk factors.Retail sentiment surged on Stocktwits, where message volume was marked “extremely high” and sentiment labeled “extremely bullish.”&nbsp;One user speculated the stock could rally to $2, while another suggested it looked “set up nicely” to retest the $1.05 pre-market high.<stembedurl>https://stocktwits.com/Netplus1/message/613838869</stembedurl><stembedurl>https://stocktwits.com/Chrismg8/message/613837620</stembedurl>Shares of Zyversa have fallen 37.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps

ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients. 

Equity

Peering Into ZyVersa Therapeutics's Recent Short Interest

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data...

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA  Get Free Report) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 646,000 shares...

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical...

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator  VAR 200 in Patients with Diabetic Kidney Disease

Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration...

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled  Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.ZyVersa is...

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Growth in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA  Get Free Report) was the target of a large growth in short interest in February. As of February 29th, there was short interest totalling 1,190,000...

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate...

ZyVersa Therapeutics highlights data from publication on IC 100

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

Current Price	$0.1398
Prev Close	$0.142
Open	$0.13
Dividend Yield	0.00%
50-Day Moving Average	$0.3046
Beta	0.40
Avg. Volume	51,464.05
PE Ratio	-0.03

52-Week High	$3.37
52-Week Low	$0.11
Market Capitalization	$1.15M
EPS (Annual)	-$8.48
Price to Book	0.11
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ZVSA
ZyVersa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZVSA News

ZVSA ZyVersa Therapeutics Inc